Low-Molecular-Weight Heparins and Thrombin Inhibitors — CPB 0346 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0346 governing low-molecular-weight heparin (LMWH) and thrombin inhibitor coverage, effective September 26, 2025. If your team bills HCPCS J1645 (dalteparin), J0883–J0899 (argatroban), or any of the surgical CPT codes tied to VTE prophylaxis, read this before submitting your next claim.

This update touches a wide range of care settings — orthopedic surgery, oncology, obstetrics, cardiology, and pediatrics — making it one of the broader anticoagulation coverage policy changes Aetna has issued in recent years. The Aetna LMWH coverage policy under CPB 0346 Aetna system now carries tighter indication-specific criteria. Miss the details, and you're looking at claim denial on anticoagulation therapy that your clinical team considers standard of care.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Low-Molecular-Weight Heparins and Thrombin Inhibitors
Policy Code	CPB 0346
Change Type	Modified
Effective Date	September 26, 2025
Impact Level	High
Specialties Affected	Orthopedic surgery, oncology, obstetrics, cardiology, hematology, pediatrics, nephrology, neurosurgery
Key Action	Audit all LMWH and thrombin inhibitor claims against updated indication-specific criteria before billing for dates of service on or after September 26, 2025

---

Aetna LMWH and Thrombin Inhibitor Coverage Criteria and Medical Necessity Requirements 2025

The Aetna LMWH coverage policy aligns with guidance from the American Heart Association and the American Society of Clinical Oncology. That framing matters for your documentation strategy — when you're building a medical necessity argument, referencing those society guidelines strengthens your case.

Aetna considers LMWHs medically necessary across 14 distinct indication categories. The sheer breadth here is worth pausing on. This isn't a narrow policy covering one procedure type — it spans surgical prophylaxis, inpatient and outpatient VTE treatment, pregnancy-related anticoagulation, pediatric use, oncology, and ECMO/hemodialysis settings.

Medical necessity is determined at the indication level. "Patient needs blood thinners" won't hold up. Your documentation needs to map to a specific approved indication, with the clinical detail to support it.

Surgical VTE Prophylaxis

For hip surgery (CPT 27130, 27132, 27134, 27137, 27138, 27125), Aetna covers LMWH prophylaxis for up to 35 days post-operatively. That duration limit is strict. Claims for day 36 and beyond won't meet medical necessity under this policy without a separate qualifying indication.

Knee surgery (CPT 27447) gets a shorter window — up to two weeks post-operatively. Arthroscopic knee procedures (CPT 29880, 29881) are listed in the code set, so document your VTE risk assessment carefully if you're billing LMWH alongside these.

Major thoracic surgery (CPT 30000–32999) qualifies for up to two weeks of LMWH prophylaxis — but only when the patient has a malignancy or a history of DVT or PE. Risk stratification documentation isn't optional here; it's the claim.

Abdominal-pelvic surgery (CPT 40490–49999) follows a two-week standard duration, with an extended four-week window available for cancer patients at high VTE risk. The operative report and oncology records need to support both the surgery and the elevated risk.

Outpatient and Inpatient VTE Treatment

For inpatient VTE treatment, Aetna covers LMWHs for venous thrombosis with or without pulmonary embolism. For outpatient settings, the policy explicitly recognizes that LMWHs require less monitoring than unfractionated heparin (UFH) — that's the clinical rationale Aetna uses to justify home-setting treatment, and it's language worth mirroring in your prior authorization requests.

Cancer-Associated VTE

This is where LMWH billing gets complicated, and where claim denial risk is highest. For cancer patients with established VTE, Aetna covers LMWHs for initial treatment (five to ten days) and continuing treatment (at least six months). After six months, indefinite anticoagulation should be considered for select patients. That word "select" is doing a lot of work. If you're billing beyond six months, make sure the oncology team has documented the rationale clearly.

Pregnancy, Prosthetic Valves, and Kawasaki Disease

Aetna covers LMWH for thromboprophylaxis in pregnant women with thrombophilic disorders, VTE treatment in pregnancy, antiphospholipid syndrome, and prosthetic heart valve anticoagulation. These indications pull from ACOG Committee Opinion guidance — cite it in your documentation.

The Kawasaki disease indication is specific: LMWH is covered for coronary thrombosis prevention in patients with large or giant aneurysms where the Z-score is ≥10 or the absolute dimension is ≥8 mm. You need those measurements in the chart.

Mechanical Heart Valves and Bridging Therapy

LMWHs are covered for members with mechanical heart valves until they're stable on vitamin K antagonists or novel oral anticoagulants (NOACs). Bridging therapy pre- and post-surgery (referenced in CPB 0200) is also covered. If you're billing bridging therapy, cross-reference CPB 0200 — Aetna links these policies together, and your documentation should reflect both.

Pediatric Use

For children two months and older, Aetna covers LMWH for short-term prophylaxis in high-risk situations (immobility, surgery, trauma), long-term management of congenital pre-thrombotic states, and when long-term oral anticoagulant therapy becomes problematic. Pediatric LMWH billing requires specific clinical indications in the chart — "patient is a child on anticoagulation" won't get the claim paid.

ECMO and Hemodialysis

The policy code set includes CPT 33946–33986 for ECMO and CPT 90935–90940 for hemodialysis. Anticoagulation in these settings is standard practice, but Aetna's medical necessity requirements still apply. Make sure your clinical documentation connects the LMWH or thrombin inhibitor use to the procedure.

Thrombin Inhibitors (Argatroban)

HCPCS J0883, J0884, J0891, J0892, J0898, and J0899 cover argatroban in both ESRD and non-ESRD formulations. Coverage is tied to the same selection criteria framework. The ESRD-specific codes (J0884, J0892, J0899) matter if you're billing anticoagulation for dialysis patients — use the right code for the right patient population or you'll generate a claim denial that's hard to appeal.

---

Aetna LMWH and Thrombin Inhibitor Exclusions and Non-Covered Indications

The policy summary was truncated at the source before listing all exclusions. Based on the available policy data, confirmed non-covered uses are not fully enumerated in this update. The real risk here is billing an off-label or unsupported indication without realizing it falls outside the 14 covered categories.

If your clinical team is using LMWHs for an indication not listed in the covered criteria above — even if it's clinically reasonable — treat it as potentially non-covered under this policy. Talk to your compliance officer before submitting those claims.

---

Coverage Indications at a Glance

---

Aetna LMWH and Thrombin Inhibitor Billing Guidelines and Action Items 2025

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for LMWH and Thrombin Inhibitors Under CPB 0346

HCPCS Codes — Covered When Selection Criteria Are Met

CPT Codes — Related to CPB 0346

Orthopedic / Hip and Knee

Respiratory System / Surgery

Code	Description Copy
30000–32999	Respiratory system / surgery (nasal, sinus, larynx, trachea, lung, thorax)

Cardiovascular System / Surgery

Code	Description Copy
33016–37799	Cardiovascular system / surgery

ECMO / Extracorporeal Life Support

Splenectomy

Digestive System / Surgery

Code	Description Copy
40490–49999	Digestive system / surgery

Nervous System / Surgery

Code	Description Copy
61000–64999	Nervous system / surgery

Eye and Ocular Adnexa / Surgery

Code	Description Copy
65091–68899	Eye and ocular adnexa / surgery

Hemodialysis

Administration / Infusion Codes

Physical Medicine

Code	Description Copy
97016	Application of vasopneumatic devices

Key ICD-10-CM Diagnosis Codes

This policy includes 487 ICD-10-CM codes. The full list is available in the Aetna CPB 0346 source document. Your billing team should confirm that the ICD-10-CM codes on your claims map directly to one of the 14 covered indications. Common relevant code families include deep vein thrombosis (I82.x), pulmonary embolism (I26.x), obstetric anticoagulation (O22.x, O26.x), and acute MI (I21.x). If you need the full 487-code list reviewed, pull the source policy at app.payerpolicy.org/p/aetna/0346 or talk to your billing consultant.

---